Vilin Bio Med
NSE: VILINBIO · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vilin Bio Med's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vilin Bio Med Ltd is an ISO-9001-2008 and GMP certified pharmaceutical manufacturer established in 2005. The company specialises in producing a wide range of formulations including oral liquids, tablets, capsules, and external preparations.
Business Model
The company operates as a B2B manufacturer, supplying pharmaceutical formulations in bulk to other manufacturers, marketers, and traders. It does not market products under its own brand name, focusing instead on contract manufacturing and wholesale distribution.
- Certifications:ISO-9001-2008, GMP
Growth Outlook
Growth is primarily driven by the demand for outsourced pharmaceutical manufacturing and the expansion of its diverse product portfolio across beta and non-beta lactam categories.
Key Risks
- Regulatory Compliance. Failure to maintain GMP and other international quality certifications could lead to production halts or loss of business from pharmaceutical clients.
- Client Concentration. As a bulk supplier without its own brand, the company is highly dependent on the procurement strategies and market performance of its third-party clients.
- Input Cost Volatility. Fluctuations in the prices of Active Pharmaceutical Ingredients (APIs) and raw materials can significantly impact manufacturing margins.
- Sector Competition. The pharmaceutical contract manufacturing space is highly competitive, putting constant pressure on pricing and operational efficiency.
Start your research today
Unlock AI insights, financials, peers and live data on Vilin Bio Med and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Vilin Bio MedVILINBIO | ₹80 Cr | — | — | — | 7.6% | — | — | +127.8% |
TranschemTRANSCHEM | ₹502 Cr | 75.62 | 52.99 | -100.0% | 177.7% | 8.3% | 10.6% | +600.8% |
Albert DavidALBERTDAVD | ₹501 Cr | 21.67 | 13.19 | 11.4% | 11.0% | 5.8% | 7.5% | +10.3% |
Haleos Labs LimitedHALEOSLABS | ₹457 Cr | 28.51 | 12.83 | -3.1% | 13.6% | 7.4% | 10.3% | — |
Medicamen BiotecMEDICAMEQ | ₹434 Cr | 43.00 | 19.76 | 24.7% | 11.3% | 4.1% | 6.2% | +5.9% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹420 Cr | 12.30 | 8.20 | — | 30.0% | 16.7% | 21.5% | -15.2% |
As of Mar 2026
Financials
Vilin Bio Med
NSE: VILINBIO · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Vilin Bio Med's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Vilin Bio Med Ltd is an ISO-9001-2008 and GMP certified pharmaceutical manufacturer established in 2005. The company specialises in producing a wide range of formulations including oral liquids, tablets, capsules, and external preparations.
Business Model
The company operates as a B2B manufacturer, supplying pharmaceutical formulations in bulk to other manufacturers, marketers, and traders. It does not market products under its own brand name, focusing instead on contract manufacturing and wholesale distribution.
- Certifications:ISO-9001-2008, GMP
Growth Outlook
Growth is primarily driven by the demand for outsourced pharmaceutical manufacturing and the expansion of its diverse product portfolio across beta and non-beta lactam categories.
Key Risks
- Regulatory Compliance. Failure to maintain GMP and other international quality certifications could lead to production halts or loss of business from pharmaceutical clients.
- Client Concentration. As a bulk supplier without its own brand, the company is highly dependent on the procurement strategies and market performance of its third-party clients.
- Input Cost Volatility. Fluctuations in the prices of Active Pharmaceutical Ingredients (APIs) and raw materials can significantly impact manufacturing margins.
- Sector Competition. The pharmaceutical contract manufacturing space is highly competitive, putting constant pressure on pricing and operational efficiency.
Start your research today
Unlock AI insights, financials, peers and live data on Vilin Bio Med and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2026